Arbel R, et al. - Researchers compared ezetimibe vs evolocumab treatment—taking into account drug costs based on 2018 US prices—for secondary prevention of one major adverse cardiovascular events (MACE) in patients with type 2 diabetes. They assessed the FOURIER and IMPROVE-IT trials to extract the number needed to treat with evolocumab or with ezetimibe for avoiding MACE, respectively. They also carried out sensitivity and scenario analyses to overcome variances in terms of population risk, efficacy of therapies, and costs. According to findings, ezetimibe treatment was a major cost-saving strategy for preventing MACE in this patient population because of the consistent costs savings observed in association with ezetimibe vs evolocumab treatment in all analyses performed, except for the case where evolocumab price was significantly reduced and the branded ezetimibe was used.